促凝血药物开发


  1. 术与外伤引起的急性出血:目前由手术与外伤引起的急性出血还没有有效的止血药物。为填补这一空白,555000a会员中心生物正在开发一种全新的融合蛋白新药。该药物结合了组织因子的强力促凝血特性与纳米抗体的靶向性。临床前实验显示该融合蛋白不仅适用与急性出血性疾病,同时还可应用于部分对凝血因子治疗产生抗药性的血友病病人。



Share to:
13th Kechuang St. Beijing Economic Development Area, Beijing
13520295482
info@neoletix.com
Passionate for life and future Dedicated to the research and development in the area of hemostasis, thrombosis, rare diseases and cancer therapies.